Nutriband Inc. (NASDAQ: NTRB) Advances Abuse-Deterrent Buprenorphine Therapy with AVERSA Technology

Stock Information for Nutriband Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Nutriband Inc.

Nutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA Approval
Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval
Nutriband Inc. added to the Russell Microcap® Index, Russell Microcap Growth® Index, Russell 3000E® Index and Russell 3000E Growth® Index
Nutriband and Kindeva Complete Commercial Manufacturing Process Scale-up for Aversa(TM) Fentanyl Abuse Deterrent Fentanyl Patch
Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology
Nutriband Inc. to present at the 2025 Noble Capital Markets Virtual Equity Conference
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Gareth Sheridan, CEO of Nutriband Inc.

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.